Nymox Pharmaceutical (NYMX)

Revenue in 2023 (TTM): N/A

In 2022 the company made a revenue of N/A a decrease over the revenue in the year 2021 that were of N/A. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Nymox Pharmaceutical from 1997 to 2023

Annual revenue

Year	Revenue	Change
2023 (TTM)	N/A
2022	N/A
2021	N/A	-100%
2020	NZ$0 M	-95.94%
2019	NZ$0.17 M	-61.69%
2018	NZ$0.44 M	41.33%
2017	NZ$0.31 M	-22.97%
2016	NZ$0.4 M	-89.85%
2015	NZ$4.03 M	7.17%
2014	NZ$3.76 M	-7.9%
2013	NZ$4.08 M	9.44%
2012	NZ$3.73 M	-6.38%
2011	NZ$3.98 M	344.39%
2010	NZ$0.89 M	56.76%
2009	NZ$0.57 M	-22.41%
2008	NZ$0.73 M	30.42%
2007	NZ$0.56 M	-9.44%
2006	NZ$0.62 M	0.1%
2005	NZ$0.62 M	38.27%
2004	NZ$0.45 M	46.38%
2003	NZ$0.3 M	-54.88%
2002	NZ$0.68 M	20.74%
2001	NZ$0.56 M	11.14%
2000	NZ$0.5 M	-24.54%
1999	NZ$0.67 M	18.35%
1998	NZ$0.57 M	10.25%
1997	NZ$0.51 M

Revenue for similar companies or competitors

Company	Revenue	Revenue differencediff.	Country
Abbott Laboratories ABT	NZ$70.62 B	N/A	🇺🇸 USA
Pfizer PFE	NZ$95.34 B	N/A	🇺🇸 USA
Quest Diagnostics DGX	NZ$16.34 B	N/A	🇺🇸 USA
Eli Lilly LLY	NZ$70.02 B	N/A	🇺🇸 USA
Johnson & Johnson JNJ	NZ$150.27 B	N/A	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Revenue for Nymox Pharmaceutical (NYMX)

Revenue in 2023 (TTM): N/A